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Abstract 
 
Background: To determine the net clinical benefit of a new treatment strategy, information on both 
survival and patient-reported outcomes (PROs) is required. However, to make an adequately 
informed decision, PRO evidence should be of sufficiently high quality. 
Objective: To investigate the methodological quality of PRO reporting in randomized controlled trials 
(RCTs) in patients with brain tumours, and to assess the proportion of studies that should impact 
clinical decision-making. 
Methods: We conducted a systematic literature search in several databases covering January 2004 to 
March 2012. We selected relevant RCTs and retrieved the following data: (1) basic trial demographics 
and PRO characteristics, (2) quality of PRO reporting, and (3) risk of bias. Studies that should impact 
clinical decision-making based on their methodological robustness were analysed systematically.  
Results: We identified 14 RCTs, representing over 3000 glioma patients. Only two RCTs (14%) 
satisfied sufficiently many key methodological criteria to provide high-quality PRO evidence, and  
should therefore impact clinical decision-making. Important methodological limitations in other 
studies were lack of reporting of the extent (43%) and reasons (86%) of missing data and statistical 
approaches to handle this (71%). PRO results were not interpreted in 79% of the studies and clinical 
significance was not discussed in 86%. Studies with high-quality PRO evidence generally showed 
lower risk of bias.  
Conclusions: Investigators involved in brain tumour research should pay special attention to 
methodological challenges identified in current work. The level of PROs reporting should continue to 
improve in order to facilitate a critical appraisal of study results.  
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1 Introduction 
 
Although primary brain tumours constitute only 2% of all adult cancers[1], they result in a 
disproportionate share of cancer morbidity and mortality. Gliomas are the most frequent primary 
brain tumours in adults, and prognosis depends on histological tumour type, grade and tumour 
genetics.[2] Typically, patients with low-grade gliomas live longer than patients with higher grade 
gliomas. However, despite multimodal treatment with surgery, radiotherapy and chemotherapy, 
gliomas remain largely incurable.[2, 3] 
Traditional outcome measures in randomized clinical trials (RCTs) are overall and 
progression-free survival. The incurable nature of gliomas has led to the recognition that palliation 
and maintenance or improvement of health-related quality of life (HRQoL) are just as important as 
prolonged survival. Consequently, HRQoL has become an important outcome measure in clinical 
brain tumour research.[4-7] HRQoL is a patient-reported outcome (PRO), reflecting the patient’s 
perspective[8], and is a multidimensional concept covering physical, psychological and social 
domains as well as symptoms induced by the disease and its treatment.[9] Several PRO measures are 
available, ranging from one-dimensional (measuring a single aspect of HRQoL, such as fatigue) to 
multidimensional measures. 
To determine the net clinical benefit of a new treatment strategy, information on both 
survival and HRQoL is required. The benefits of a new treatment strategy in terms of prolonged 
survival have to be carefully weighed against the side-effects of this treatment. HRQoL 
measurements should therefore be included in RCTs. In addition, it is important that PROs generate 
high-quality evidence to be of value. Inadequate or poorly designed RCTs including PRO 
measurements, or simply reporting insufficient PRO information, may limit their ability to inform 
clinical decision-making. In 2002, a systematic review showed that many RCTs in brain tumour 
patients which included PRO had methodological limitations, hampering the interpretation of the 
results.[10] 
 The primary objective of this study was to investigate the methodological quality of PRO 
reporting in RCTs of primary brain tumours published since 2004. The secondary objective was to 
assess the proportion of studies that should impact clinical decision-making based on their 
methodological robustness.  
 
2     Methods 
 
2.1 Search strategy for identification of studies 
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We conducted a systematic literature search in the e-resources PubMed/Medline, the Cochrane 
Library, PsycINFO, and PsycARTICLES covering January 2004 to March 2012. The search strategy 
consisted of a combination of two strings, one related to PRO measures and one related to primary 
brain tumours (see supplementary file for full search string).  
In PubMed/Medline, the search strategy was restricted to RCTs. Moreover, only English-language 
articles were considered. All retrieved titles and abstracts were screened, and full-texts of potential 
relevant articles were read and the reference lists of these articles were screened for additional 
studies. In addition, experts in the field were contacted to identify possible relevant articles that 
were not retrieved in the electronic search. 
 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines 
were followed to document details on the search strategy and selection processes.[11] 
 
2.2 Criteria for considering studies 
 
2.2.1 Type of participants 
Studies were considered to be eligible if adult (>18 years) patients were included with histologically 
confirmed primary brain tumours, or those with recurrence, regardless of the type and grade of the 
tumour. Studies involving patients with brain metastases were excluded. 
 
2.2.2 Type of intervention 
 
Any RCT comparing conventional treatments (i.e. chemotherapy, radiotherapy, surgery and target 
therapy) was eligible for inclusion. Studies comparing psychosocial interventions or complementary 
and alternative medicine were excluded. 
 
2.2.3 Type of outcome measures examined 
 
All studies including a PRO measure, either as primary or secondary outcome measure, were 
considered eligible. Measures assessing the impact of the disease and treatment-related effects were 
considered, including both multidimensional HRQoL measures as well as other types of PRO 
measures. Studies evaluating adherence to therapy or satisfaction were excluded. 
 
2.2.4 Type of studies 
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Only original studies were considered and they were eligible if they described an RCT comparing 
different conventional medical treatment modalities or symptom management strategies, and if a 
minimum of 50 primary brain tumour patients (overall) were included. When the RCT comprised a 
heterogeneous population, consisting of different cancer types, the study was excluded because of 
possible difficulties in interpreting PRO results relating specifically to primary brain tumour patients. 
 
2.3 Methods of study evaluation 
 
Data were gathered through the EORTC Quality of Life Group PROMOTION (Patient-Reported 
Outcomes Measurements Over Time in Oncology) Registry (http://promotion.gimema.it/) which 
stores information on cancer RCTs having included a PRO evaluation. More details on this project 
have been previously published.[12] Two reviewers (E.S. and M.J.) independently reviewed all 
identified studies. When disagreements occurred, the paper was reviewed again and remaining 
discrepancies were solved by consensus or by consulting a third reviewer (F.E.).  
 On several trials, multiple articles were published. In these cases, relevant data from all 
articles were combined.  
 
2.4 Type of information extracted and definition of high quality PRO study 
 
We extracted different types of information from each RCT. First, basic trial demographics and 
clinical and PRO characteristics were extracted, such as the overall study sample size, types of 
intervention, type of PRO questionnaire used, and main PRO and clinical outcomes.  
Second, the level of PRO reporting was assessed using the recently published 
recommendations by the International Society for Quality of Life Research (ISOQOL).[13] The ISOQOL 
checklist consists of 17 items that should be reported in all RCTs, irrespective of the type of PRO and 
whether the PRO is used as primary or secondary endpoint. When a PRO is the primary endpoint, an 
additional 11 items should be reported.[13] As exception to the checklist, we divided the item about 
‘missing data’ into two items (extent of missing data and statistical approaches to deal with missing 
data), to better investigate the possible discrepancies between reporting of actual missing PRO data 
as opposed to reporting of statistical methods to address this issue. To estimate the potential impact 
of PRO evidence on clinical decision-making, we needed a definition of ‘high-quality’ for PRO 
evidence. In line with previous work[12], we propose that at least two-thirds of the recommended 
ISOQOL criteria must be satisfied in order to be classified as high-quality evidence. Additional details 
have been previously reported.[14] 
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Third, using the Cochrane Risk of Bias Tool, the RCTs were assessed for risk of bias.[15] Types 
of bias assessed were selection bias, performance bias, detection bias, attrition bias and reporting 
bias. The risk of bias was divided into three categories using previously reported definitions: low risk, 
unclear or high risk of bias.[12] 
 
3 Results 
 
The literature search yielded 3404 records published between January 2004 and March 2012 which 
were screened for eligibility. A total of 18 papers was identified, comprising 14 RCTs which enrolled 
over 3000 glioma patients. Figure 1 shows  a detailed description of the selection procedure. 
 
3.1 Overview of study demographics and patient-reported outcomes assessment 
 
In all 14 RCTs, PRO measurements were a secondary endpoint. Most (64%) RCTs were multi-centre 
international studies and half (50%) of the RCTs had a sample size of >200 patients. Patients with 
glioblastoma were mostly studied (86%). 
 All studies used previously validated PRO instruments. The two most frequently used PRO 
instruments were the European Organisation of Research and Treatment of Cancer (EORTC) QLQ-C30 
and the Functional Assessment of Cancer Therapy-General (FACT-G) in nine (64%) and four studies 
(29%), respectively. These instruments were used alone or in conjunction with tumour-specific 
measures (EORTC QLQ-BN20 and the FACT-Brain). A difference in PRO results between the treatment 
arms was found in three RCTs (23%). Further details are depicted in Table 1. 
 
3.2 Overview of methodological PRO quality according to ISOQOL criteria 
 
According to the predefined criteria, two RCTs[6, 7, 16-19] provided ‘high-quality’ evidence (Table 2). 
Major limitations in reporting included the lack of documentation of the rationale for the PRO 
instrument used (86%) and lack of a description of the PRO hypothesis and specification of the 
relevant PRO domains that were analysed (86%). Moreover, none of the trials documented the mode 
of PRO administration (i.e. on paper, by telephone, electronically) and the methods of data 
collection. The level of documentation of details on missing data was highly variable: only two 
studies (14%) reported reasons for missing data, four studies (29%) described the statistical 
approaches to deal with missing data, while eight studies (57%) reported on the extent of missing 
data. Furthermore, the majority of the trials (57%) did not describe the baseline PRO characteristics. 
The clinical significance of PRO findings was discussed in only two trials (14%), whereas four trials 
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(29%) discussed PRO findings in the context of other clinical outcome measures. Lastly, a minority of 
the trials discussed the limitations of the PRO components in the trial (29%) or the generalizability 
issues uniquely related to the PRO results (14%). 
In contrast, most studies did report whether the PRO was a primary or secondary outcome 
measure (93%). Also, details on PRO data collection schedule were provided in the majority of the 
studies (93%). 
  
3.3 Risk of bias 
 
For several types of bias, the risk across RCTs was similar for studies that provided high- and low-
quality PRO evidence (Figure 2). Nevertheless, two studies with low-quality PRO evidence (17%) had 
a high risk of performance bias, where neither of the two studies with high-quality PRO evidence had 
a high risk for this type of bias. Moreover, most studies with low-quality PRO evidence (67%) had a 
high risk of reporting bias and attrition bias (58%), while both studies with high-quality PRO evidence 
were attributed a low risk.  
 
3.4 Overview of treatment recommendations based on high-quality PRO studies 
 
We identified two RCTs that provided ‘high-quality’ PRO evidence and should therefore be 
considered to adequately influence clinical decision-making. The first RCT compared radiotherapy 
alone with radiotherapy plus concomitant and adjuvant temozolomide in patients with newly 
diagnosed glioblastoma.[17, 18] This study showed that the combination of temozolomide and 
radiotherapy led to clinically meaningful and significant longer overall and progression-free survival 
rates. This prolonged survival was achieved without a lasting negative impact on HRQoL. Although 
patients undergoing treatment with temozolomide plus radiotherapy reported significant lower 
social functioning compared to patients undergoing radiotherapy alone, this decline in HRQoL was 
temporary. Similar results were found for nausea and vomiting, appetite loss, and constipation: 
radiotherapy plus temozolomide resulted in a temporary higher symptom burden. Other HRQoL 
scales did not differ between the two treatment arms during follow-up.[6] Concomitant and adjuvant 
radiochemotherapy with temozolomide is now the standard of care for newly diagnosed 
glioblastoma patients[20]; this study showed that the benefits of prolonged survival outweigh the 
temporary negative effects of this treatment on HRQoL.   
The second RCT compared radiotherapy alone with radiotherapy plus adjuvant procarbazine, 
lomustine and vincristine (PCV) chemotherapy in patients with newly diagnosed anaplastic 
oligodendrogliomas and oligoastrocytomas.[19] After a median follow-up of 60 months, overall 
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survival rate was similar for the two treatment arms while progression-free survival was significantly 
longer in patients treated with radiotherapy plus PCV chemotherapy.[19] A recent update on this 
study has shown that, after median follow-up of 140 months, both overall and progression-free 
survival rates were significantly prolonged in the radiotherapy plus PCV chemotherapy arm, in 
particular in patients with co-deleted 1p/19q.[21] Addition of PCV chemotherapy to radiotherapy 
resulted in a decreased HRQoL during and shortly after receiving PCV chemotherapy: patients 
reported more nausea and vomiting, appetite loss and drowsiness.[7] However, this decline in 
HRQoL was clinically not meaningful, and transient. Based on the survival benefit, treatment with 
radiotherapy plus PCV chemotherapy is recommended for patients with 1p/19q co-deleted 
anaplastic oligodendrogliomas and oligoastrocytomas[20]. The ‘high-quality’ PRO results support the 
choice for this treatment strategy: the temporary negative effects of the experimental treatment 
strategy on HRQoL seem to be outweighed by the survival benefit. For those without co-deletion, 
radiotherapy alone remains the standard of care.[20] 
 
4 Discussion 
 
In the last decade, more than 3000 glioma patients have been included in 14 RCTs to obtain 
information on the impact of different treatment strategies, both in terms of survival and PROs. This 
systematic literature review showed that two RCTs could be classified as ‘high-quality’ studies with 
respect to PRO evidence[6, 7] and could therefore facilitate critical appraisal and interpretation of 
the results necessary for clinical decision-making.[22]  
 Compared to the previous systematic review[10], which identified only five RCTs including a 
PRO measure in a period >20 years, the absolute amount of RCTs including a PRO measure has 
increased in the last decade. However, current data indicate that level of PRO reporting has not 
improved much. Previously, issues such as documentation of missing data, description of PRO 
hypothesis, description of clinical significance of PRO findings, and a description of the methods of 
administration were reported in 60%, 40%, 20% and none of the RCTs, respectively.[10] Similarly, the 
current review reveals that these issues were reported in 57%, 7%, 14% and none of the RCTs. On the 
other hand, where previously poorly validated instruments were used, all RCTs in the current review 
used validated and reliable PRO instruments. Awareness of sufficient reporting of PRO results is still 
warranted, and key guidelines on how to conduct and report PRO measures are available.[13] This 
applies not only to brain tumour research, because similar methodological limitations were found in 
other cancers, such as prostate or lung cancer.[12, 23] 
A major limitation of all RCTs, regardless of publication date, is an adequate description of 
missing data. Missing data is a major source of bias and a common problem in many research 
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areas.[24] Frequent reasons for missing data in brain tumour trials are administrative failure, patient 
refusal and poor health status of the patient.[25] As a result, patients with poor prognostic factors 
and a poor response to treatment are underrepresented during follow-up.[26] This has implications 
for the interpretation of the results. It is therefore of utmost importance that studies report the 
amount of missing data and their methods of analysis. From a practical point of view, the amount of 
missing data can be decreased by using electronic data capture[27] or proxy measures. 
Another major limitation is that the majority of RCTs lacks an interpretation of PRO findings, 
especially in terms of clinical significance. A significant difference in PRO between two treatment 
arms does not necessarily imply that this difference is also clinically meaningful for patients.[28] 
Moreover, when no differences in survival are found between treatment arms, PRO results can be 
highly informative to evaluate the net clinical benefit of a new treatment strategy. Also, in many 
studies PROs are assessed up to, but not beyond, tumour progression. This will hamper the 
evaluation of late treatment effects, especially in trials where a difference in progression-free 
survival leads to a difference in observation time. Data collection after tumour progression should 
therefore be included in future trials.[29, 30] 
 Although the quality of reporting of PRO evidence was classified as low in most RCTs 
published since 2004, this does not mean that the trial design was poor. These RCTs may have 
assessed and analysed PROs correctly, but failed to report the procedures and results adequately, 
resulting in PRO evidence classified as low-quality. A possible explanation for the poor reporting of 
PRO procedures and results is that PROs are used as secondary outcome measures. This means that 
results on PRO assessment are included in the main paper, next to outcome measures such as overall 
and progression-free survival, leaving limited room for a detailed description of PRO results. 
Therefore, researchers need to become aware of the recommended methodologies for reporting 
PRO-related outcomes, in order to facilitate critical appraisal and interpretation of the results 
necessary for clinical decision-making. We therefore suggest reporting PROs in a separate 
publication, possibly in the same journal to reach the same target audience. Moreover, both RCTs 
that provided high-quality PRO evidence were conducted by the EORTC, an organization with a 
longstanding tradition in HRQoL research. Indeed, the EORTC Quality of Life Group implemented 
standardized procedure for HRQOL implementation cancer trials already several years ago.[31] 
 This paper has limitations. Although a comprehensive search strategy was used, it is possible 
that not all RCTs comprising PRO components were identified. Moreover, this review covers RCTs 
published between 2004 and 2012, thereby excluding more recently published RCTs[32-35] and 
those published between 2002 (previous review covers years <2002[10]) and 2004. This may result in 
an underestimation of the amount of studies with high-quality PRO evidence, and therefore a lack to 
detect an improvement in PRO reporting over time. It will thus be important to keep monitoring and 
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evaluating future studies to possibly find a quality improvement over time. Another limitation of this 
study is that the definition of ‘high-quality’ PRO evidence is based on methodological grounds solely. 
However, evaluation of the methodological quality of PRO evidence is based on recommendations 
that are generated by an international task force endorsed by a major scientific society.[13, 36] A 
challenge, however, is to determine the tangible impact of ‘high-quality’ PRO studies on clinical 
decision-making. Although treatment recommendations in oncology endorse that quality of life is of 
highest priority and should guide clinical guidance[37], most recommendations seem to be based on 
survival outcomes only. Moreover, the actual impact on clinical decision-making also depends on the 
specific findings of a study, implying that studies with low-quality PRO evidence might have had a 
large impact as well. Lastly, we have to acknowledge that with only 14 studies, the estimates may not 
be very accurate.  
In conclusion, quality of PRO reporting was evaluated in 14 RCTs in patients with primary 
brain tumours and found to be of sufficient quality to be valuable for clinical decision-making in two 
RCTs. High-quality PRO evidence is necessary to determine the net clinical benefit of treatment 
strategies, in conjunction with survival data. Both RCTs that included high-quality PRO evidence 
resulted in treatment recommendations, showing that the new treatment strategies were not only 
effective in terms of survival, but also without a (lasting) detrimental effect on HRQoL. Overall, this 
systematic review indicates the need to keep improving PRO reporting in brain tumour trials, in order 
to facilitate critical appraisal and interpretation of results necessary to better inform clinical decision-
making. 
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Table 1. RCT demographic characteristics of studies identified. 
 
Table 2 Level of Patient-Reported Outcomes (PRO) reporting  
 
Table 3. Randomized Controlled Trials: basic study characteristics. 
 
 
Fig.1 - Schematic breakdown of literature search results of Brain Randomized Controlled Trials 
(Preferred Reporting Items for Systematic Reviews and Meta-analysis).  
* PRO= patient-reported outcomes. 
 
 
Figure 2. Risk bar chart showing risk of bias across RCTs by quality of PRO reporting.  
